BR112016014151B1 - Pirirmidopirimidinonas úteis como inibidores de quinases wee-1 - Google Patents

Pirirmidopirimidinonas úteis como inibidores de quinases wee-1 Download PDF

Info

Publication number
BR112016014151B1
BR112016014151B1 BR112016014151-2A BR112016014151A BR112016014151B1 BR 112016014151 B1 BR112016014151 B1 BR 112016014151B1 BR 112016014151 A BR112016014151 A BR 112016014151A BR 112016014151 B1 BR112016014151 B1 BR 112016014151B1
Authority
BR
Brazil
Prior art keywords
methyl
group
amino
pyrimidin
dichlorophenyl
Prior art date
Application number
BR112016014151-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016014151A2 (cg-RX-API-DMAC7.html
Inventor
Timothy Harrison
Graham Trevitt
Peter Robin Hewitt
Colin Roderick O'dowd
Frank Burkamp
Andrew John Wilkinson
Steven D. Shepherd
Hugues Miel
Original Assignee
Almac Discovery Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Limited filed Critical Almac Discovery Limited
Publication of BR112016014151A2 publication Critical patent/BR112016014151A2/pt
Publication of BR112016014151B1 publication Critical patent/BR112016014151B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016014151-2A 2013-12-19 2014-12-19 Pirirmidopirimidinonas úteis como inibidores de quinases wee-1 BR112016014151B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322602.2 2013-12-19
GBGB1322602.2A GB201322602D0 (en) 2013-12-19 2013-12-19 Pharmaceutical compounds
PCT/GB2014/053793 WO2015092431A1 (en) 2013-12-19 2014-12-19 Pyrimidopyrimidinones useful as wee-1 kinase inhibitors

Publications (2)

Publication Number Publication Date
BR112016014151A2 BR112016014151A2 (cg-RX-API-DMAC7.html) 2017-08-08
BR112016014151B1 true BR112016014151B1 (pt) 2023-01-17

Family

ID=50071157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014151-2A BR112016014151B1 (pt) 2013-12-19 2014-12-19 Pirirmidopirimidinonas úteis como inibidores de quinases wee-1

Country Status (28)

Country Link
US (1) US9850247B2 (cg-RX-API-DMAC7.html)
EP (1) EP3083625B1 (cg-RX-API-DMAC7.html)
JP (1) JP6437559B2 (cg-RX-API-DMAC7.html)
KR (1) KR102405462B1 (cg-RX-API-DMAC7.html)
CN (1) CN105829315B (cg-RX-API-DMAC7.html)
AU (1) AU2014369457B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016014151B1 (cg-RX-API-DMAC7.html)
CA (1) CA2933755C (cg-RX-API-DMAC7.html)
CY (1) CY1120035T1 (cg-RX-API-DMAC7.html)
DK (1) DK3083625T3 (cg-RX-API-DMAC7.html)
ES (1) ES2650013T3 (cg-RX-API-DMAC7.html)
GB (1) GB201322602D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20180080T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037908T2 (cg-RX-API-DMAC7.html)
IL (1) IL245672B (cg-RX-API-DMAC7.html)
LT (1) LT3083625T (cg-RX-API-DMAC7.html)
MX (1) MX371108B (cg-RX-API-DMAC7.html)
NO (1) NO3083625T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ720178A (cg-RX-API-DMAC7.html)
PL (1) PL3083625T3 (cg-RX-API-DMAC7.html)
PT (1) PT3083625T (cg-RX-API-DMAC7.html)
RS (1) RS56731B1 (cg-RX-API-DMAC7.html)
RU (1) RU2691105C1 (cg-RX-API-DMAC7.html)
SG (1) SG11201603814TA (cg-RX-API-DMAC7.html)
SI (1) SI3083625T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800020T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015092431A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201603337B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364247B2 (en) * 2015-04-21 2019-07-30 Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine Preparation and use of novel protein kinase inhibitors
CA3003737C (en) * 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
US10703759B2 (en) 2016-11-16 2020-07-07 Impact Therapeutics, Inc 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Bmpシグナル阻害化合物
US10954253B2 (en) 2017-01-23 2021-03-23 Shijiazhuang Sagacity New Drug Development Co., Ltd. 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
US11345710B2 (en) 2017-07-10 2022-05-31 Impact Therapeutics (Shanghai), Inc Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
RS65901B1 (sr) 2017-11-01 2024-09-30 Wuxi Biocity Biopharmaceutics Co Ltd Makrociklično jedinjenje koje služi kao wee1 inhibitor i primene istog
US12220415B2 (en) 2018-02-28 2025-02-11 The Regents Of The University Of Colorado, A Body Corporate WEE1 kinase inhibitors and methods of treating cancer using the same
EA202190885A1 (ru) * 2018-09-27 2021-06-25 Бетта Фармасьютикалз Ко., Лтд Ингибитор fgfr4 и его применение
EP3875460A4 (en) 2018-10-26 2022-07-20 Wuxi Biocity Biopharmaceutics Co., Ltd. PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF
AU2019413360B2 (en) 2018-12-28 2025-05-22 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US20220194960A1 (en) 2019-03-22 2022-06-23 Shouyao Holdings (beijing) Co., Ltd. Wee1 inhibitor and preparation and use thereof
EP3952879A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
EP3952878A4 (en) * 2019-04-09 2023-01-04 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND THEIR USES
JP2022526831A (ja) 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
FI3964510T3 (fi) 2019-04-30 2024-07-24 Wuxi Biocity Biopharmaceutics Co Ltd Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö
CN112142763B (zh) * 2019-06-28 2024-01-26 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
US20230159540A1 (en) 2020-06-17 2023-05-25 Wigen Biomedicine Technology (shanghai) Co., Ltd. PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR
US20230416247A1 (en) * 2020-10-01 2023-12-28 University Of Washington Drug-like molecules and methods for the therapeutic targeting of microrna-21
WO2022129281A1 (en) * 2020-12-18 2022-06-23 Glaxosmithkline Intellectual Property Development Limited Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors
EP4262978A1 (en) * 2020-12-18 2023-10-25 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases
AU2022265032A1 (en) 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
AU2022297176A1 (en) 2021-06-25 2024-01-04 Korea Research Institute Of Chemical Technology Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof
CN116462687B (zh) 2022-01-18 2025-01-07 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN116836184B (zh) * 2022-03-25 2025-07-25 药雅科技(上海)有限公司 Wee1激酶抑制剂的制备及其应用
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
CN117402162A (zh) 2022-07-13 2024-01-16 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
SG150544A1 (en) 2004-03-15 2009-03-30 Hoffmann La Roche Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
US8198281B2 (en) 2007-04-25 2012-06-12 Merck Sharp & Dohme Corp. Crystalline forms of dihydropyrazolopyrimidinone
PT2168966T (pt) 2007-06-15 2017-01-02 Msd Kk Derivado de bicicloanilina
CA2703489A1 (en) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
AU2009325398A1 (en) * 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
JP5886310B2 (ja) * 2010-12-06 2016-03-16 グラクソ グループ リミテッドGlaxo Group Limited Lp−PLA2により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
WO2012085167A1 (en) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
TWI532742B (zh) * 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
WO2013013031A1 (en) * 2011-07-19 2013-01-24 Abbvie Inc. Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase
EP2776434A1 (en) 2011-10-20 2014-09-17 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
ES2606640T3 (es) * 2012-02-23 2017-03-24 Abbvie Inc. Inhibidores de cinasas de tipo piridopirimidinona
CN102816164A (zh) * 2012-08-31 2012-12-12 北京理工大学 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法

Also Published As

Publication number Publication date
JP6437559B2 (ja) 2018-12-12
JP2017500335A (ja) 2017-01-05
RU2016123363A (ru) 2018-01-25
AU2014369457B2 (en) 2018-08-09
CN105829315B (zh) 2019-03-08
RS56731B1 (sr) 2018-03-30
SG11201603814TA (en) 2016-07-28
EP3083625A1 (en) 2016-10-26
IL245672B (en) 2021-10-31
CN105829315A (zh) 2016-08-03
US20160318936A1 (en) 2016-11-03
DK3083625T3 (en) 2017-12-18
WO2015092431A1 (en) 2015-06-25
KR20160098499A (ko) 2016-08-18
AU2014369457A1 (en) 2016-06-09
CA2933755A1 (en) 2015-06-25
NO3083625T3 (cg-RX-API-DMAC7.html) 2018-03-31
GB201322602D0 (en) 2014-02-05
PL3083625T3 (pl) 2018-03-30
US9850247B2 (en) 2017-12-26
CY1120035T1 (el) 2018-12-12
MX2016007801A (es) 2016-09-07
SI3083625T1 (en) 2018-03-30
LT3083625T (lt) 2017-12-27
SMT201800020T1 (it) 2018-05-02
CA2933755C (en) 2023-01-31
IL245672A0 (en) 2016-06-30
PT3083625T (pt) 2018-02-06
RU2691105C1 (ru) 2019-06-11
ES2650013T3 (es) 2018-01-16
EP3083625B1 (en) 2017-11-01
BR112016014151A2 (cg-RX-API-DMAC7.html) 2017-08-08
ZA201603337B (en) 2018-07-25
NZ720178A (en) 2022-05-27
HUE037908T2 (hu) 2018-09-28
HRP20180080T1 (hr) 2018-03-09
KR102405462B1 (ko) 2022-06-03
MX371108B (es) 2020-01-17

Similar Documents

Publication Publication Date Title
KR102405462B1 (ko) Wee-1 카이네이즈 억제제로 유용한 피리미도피리미디논
EP3529241B1 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
US10766902B2 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
JP6412920B2 (ja) 2−アミノピリド[4,3−D]ピリミジン−5−オン誘導体及びWee−1阻害薬としてのそれらの使用
JP2012511502A (ja) ジヒドロピリミドピリミジン誘導体
WO2018011570A1 (en) Wee-1 inhibiting pyridopyrimidinone compounds
CA3199082A1 (en) Heterocyclic spiro compounds and methods of use
WO2015019037A1 (en) Pharmaceutical compounds
ES3036245T3 (en) Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
JP7118509B2 (ja) 皮膚病変の治療
HK1227877B (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
HK1227877A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
BR112019004597A2 (pt) compostos e composições como inibidores de receptores endossomais do tipo toll

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/12/2014, OBSERVADAS AS CONDICOES LEGAIS